- Price
- $2.18
- Day
- +1.40%
- Mkt Cap
- $157.46M
- 52W Range
- $1.19 – $3.60
- Volume
- 213.1K
- Beta
- 0.34
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026
NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new findings presented at the Alzheimer's Association International Conference (AAIC®) 2026 in London. Following collaboration with JCR Pharmaceuticals Co., Ltd. (JCR) on EBD candidate development, studies demonstrated improved brain penetration of anti-AβO antibodies through transferrin receptor-mediated delivery across both mouse and non-human primate models. Additionally, research from early symptomatic AD patients highlighted the lived experience among ALTITUDE-AD trial participants and their study partners.
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).